| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
102.28(B) |
| Last
Volume: |
284,348 |
Avg
Vol: |
769,142 |
| 52
Week Range: |
$692.45 - $993.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
24,729 |
84,192 |
120,701 |
282,978 |
| Total Sell Value |
$23,631,267 |
$76,701,012 |
$107,160,703 |
$220,505,683 |
| Total People Sold |
7 |
13 |
15 |
17 |
| Total Sell Transactions |
14 |
38 |
55 |
116 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vagelos P Roy |
Director |
– • – |
2022-05-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
23,077 |
322,489 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2022-05-17 |
4 |
AS |
$655.40 |
$2,351,411 |
D/D |
(3,543) |
58,470 |
|
4% |
|
| Murphy Andrew J |
EVP Research |
• – – |
2022-05-16 |
4 |
D |
$648.31 |
$4,186,138 |
D/D |
(6,457) |
62,013 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2022-05-16 |
4 |
OE |
$179.13 |
$1,791,300 |
D/D |
10,000 |
68,470 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-05-02 |
4 |
AS |
$656.97 |
$722,667 |
D/D |
(1,100) |
19,644 |
|
9% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-05-02 |
4 |
OE |
$342.93 |
$377,223 |
D/D |
1,100 |
20,744 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2022-05-02 |
4 |
AS |
$643.76 |
$65,078 |
D/D |
(100) |
22,182 |
|
9% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2022-04-11 |
4 |
AS |
$729.76 |
$1,366,821 |
D/D |
(1,862) |
28,744 |
|
-15% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2022-04-08 |
4 |
D |
$736.21 |
$4,518,857 |
D/D |
(6,138) |
30,606 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2022-04-08 |
4 |
OE |
$381.92 |
$3,090,840 |
D/D |
8,000 |
32,158 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2022-04-08 |
4 |
AS |
$724.33 |
$239,780 |
D/D |
(325) |
28,744 |
|
-16% |
|
| Fenimore Christopher R. |
SVP Controller |
• – – |
2022-04-08 |
4 |
D |
$736.21 |
$4,127,193 |
D/D |
(5,606) |
26,615 |
|
- |
|
| Fenimore Christopher R. |
SVP Controller |
• – – |
2022-04-08 |
4 |
OE |
$270.43 |
$2,713,542 |
D/D |
7,450 |
30,066 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2022-04-07 |
4 |
AS |
$721.10 |
$3,687,705 |
D/D |
(5,114) |
16,900 |
|
-13% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2022-04-07 |
4 |
D |
$716.09 |
$841,406 |
D/D |
(1,175) |
29,069 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2022-04-07 |
4 |
OE |
$399.66 |
$599,490 |
D/D |
1,500 |
30,244 |
|
- |
|
| Bassler Bonnie L |
Director |
– • – |
2022-04-07 |
4 |
AS |
$725.00 |
$899,000 |
D/D |
(1,240) |
1,082 |
|
-13% |
|
| Bassler Bonnie L |
Director |
– • – |
2022-04-07 |
4 |
OE |
$380.95 |
$472,378 |
D/D |
1,240 |
2,322 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2022-04-06 |
4 |
GD |
$0.00 |
$0 |
I/I |
302 |
126,704 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2022-04-06 |
4 |
AS |
$710.04 |
$1,883,736 |
I/I |
(2,653) |
11,178 |
|
-8% |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2022-04-05 |
4 |
AS |
$710.05 |
$3,167,533 |
I/I |
(4,461) |
13,831 |
|
-7% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-04-01 |
4 |
AS |
$701.82 |
$701,820 |
D/D |
(1,000) |
19,644 |
|
-10% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-04-01 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
20,644 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2022-04-01 |
4 |
AS |
$685.71 |
$3,532,373 |
D/D |
(5,114) |
22,014 |
|
-10% |
|
| Ryan Arthur F |
Director |
– • – |
2022-04-01 |
4 |
AS |
$686.83 |
$69,281 |
D/D |
(100) |
22,282 |
|
-10% |
|
1366 Records found
|
|
Page 14 of 55 |
|
|
3.16 (0.32%) 
